Discovery of novel inhibitors for the treatment of Cancer

Tag: Atractylodin manufacture

  • Epidermal growth factor receptor (EGFR) T790M mutation may be the most

    Epidermal growth factor receptor (EGFR) T790M mutation may be the most typical mechanism which makes up about on the subject of 60% of attained resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) individuals harboring EGFR activating mutations. 0.0001) [20]. These data may recommend second-generation EGFR-TKIs could hold off the…